Anti-osteoporotic drugs
Anti-osteoporotic drugs has been studied in 6 papers since 2021: 5 observational studies in people, 1 review; 1 in the past year. The newest paper, Nov 12, 2026: “Effects of aerobic, resistance, and combined exercise on postmenopausal women with osteopenia or osteoporosis: a systematic review and network meta-analysis”.
6 papers study it3 findingsUpdated
1 new paper in 30 daysSee all 6 papers on anti-osteoporotic drugs
At a glance
The findings reach people, from one lab or study. 2 independent labs in 2 countries.
“Patients who were adherent to AOD after 12 months had a 49% lower risk of subsequent fractures than non-adherent patients (HR 0.51; 95% CI 0.35-0.72)”
1 of its findings points the other way.
- 2 independent labs in 2 countries
- 1 finding against
- Funders: Northern Norway Regional Health Authority and 2 more
- 3 of 3 findings with company ties
- Humans5
What did studies of anti-osteoporotic drugs find?
1Studies of anti-osteoporotic drugs measured one outcome, mortality.
Mortality
no changein humans1downin humans1HR 0.75
2 studies
Mortality
no changein humans1downin humans1HR 0.75
Anti-osteoporotic drugs were not clearly linked with mortality in humans (index fracture of any type) (no difference).
Humansindex fracture of any type12 months after treatment initiation
Anti-osteoporotic drugs are linked with lower mortality in humans after hip fracture, treated with anti-osteoporotic drugs (adjusted HR 0.75, 95% CI 0.59-0.96).
Humansafter hip fracture, treated with anti-osteoporotic drugs1 year
What is anti-osteoporotic drugs linked with?
1Studies link anti-osteoporotic drugs with subsequent fractures.
Subsequent fractures
downin humans1HR 0.51
1 study
Subsequent fractures
downin humans1HR 0.51
Anti-osteoporotic drugs are linked with a lower risk of subsequent fractures in humans (index fracture of any type) (HR 0.51, 95% CI 0.35-0.72).
Humansindex fracture of any type12 months after treatment initiation